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Abstract 
BACKGROUND: Evaluating the antibiotic susceptibility and resistance genes is essential in the clinical 
management of bloodstream infections (BSIs). But there are still limited studies in Northern Vietnam. 
AIM: The aim of the study was to determine the antibiotic resistance profile and characteristics of subtypes genes 
in Escherichia coli causing BSIs in Northern Vietnam. 
METHODS: The cross-sectional study was done in the period from December 2012 to June 2014 in two tertiary 
hospitals in Northern Vietnam. Tests were performed at the lab of the hospital. 
RESULTS: In 56 E. coli strains isolating 39.29 % produced ESBL. 100% of the isolates harbored blaTEM gene, 
but none of them had the blaPER gene. The prevalence of ESBL producers and ESBL non-producers in blaCTX-
M gene was 81.82%, and 73.53%, in blaSHV gene was 18.18% and 35.29%. Sequencing results showed three 
blaTEM subtypes (blaTEM 1, 79, 82), four blaCTX-M subtypes (blaCTX-M-15, 73, 98, 161), and eight blaSHV 
subtypes (blaSHV 5, 7, 12, 15, 24, 33, 57, 77). Antibiotic resistance was higher in ampicillin (85.71%), 
trimethoprim/sulfamethoxazole (64.29%) and cephazolin (50%). Antibiotics were still highly susceptible including 
doripenem (96.43%), ertapenem (94.64%), amikacin (96.43%), and cefepime (89.29%). 
CONCLUSION: In Escherichia coli causing BSIs, antibiotic resistance was higher in ampicillin, 
trimethoprim/sulfamethoxazole and cephazolin. Antibiotics was highly susceptible including doripenem, 
ertapenem, amikacin, and cefepime. 
 
 
Introduction 
 
Escherichia coli (E. coli) took the highest 
position in causative gram-negative bacterium from 
bloodstream infection (BSIs) patients in Asia region 
[1]. It led to severe infections with a high rate of shock 
and mortality [2]. Currently, the worldwide incidence of 
E. coli BSI is still increasing over time [3] with the 
overall incidence increased year on year [4] that 
suggested an increasing burden of disease [5]. The 
estimation of infections worldwide showed that third-
generation cephalosporin-resistant E. coli and K. 
pneumoniae caused 6.4 million (interval estimate 3.5-
9.2) BSIs and 50.1 million (27.5-72.8) serious 
infections in 2014[6]. In addition, it was difficult to treat 
because of the emergence of multi-drug resistance 
(MDR) of E. coli [7]. Thus, evaluating antibiotic 
susceptibility is essential to decide what types of 
antibiotics and what appropriate doses that improving 
treatment efficiency and minimizing the antibiotic 
resistance rate. Over 20 years, the susceptibility of E. 
Coli BSIs was alarmed with the prevalence 
of antimicrobial-resistant isolates was increased [8]. In 
these cases, the patients had a worse prognosis with 
partial effect on correct empirical treatment [9]. 
Antimicrobial resistance-related encoding gene in 
each E. coli strain. Extended-spectrum β-lactamases 
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(ESBLs) was one of the most important genes [10]. It 
minimized the antibiotic efficiency in treatment [11]. 
Besides, the ability of inter-transmission within 
different E. Coli strains and transmission between E. 
Coli and other bacteria led to the state of becoming 
widespread resistance genes around the world. It 
becomes public-health concern [12] with increasing 
burden and cost of hospital-acquired infections [13], 
[14]. 
In Vietnam, there was one study in Northern 
Vietnam showed 25.1% of ESBLs among 
Enterobacteriaceae causing BSIs [15] but there are 
still limited studies in Northern Vietnam. Thus, this 
study aims to determine the antibiotic resistance 
profile and characteristics of subtypes genes in 
Escherichia coli causing bloodstream infections in 
Northern Vietnam. 
 
 
Materials and Methods 
 
The cross-sectional study was done in the 
period from 12/2012 to 6/2014 in two tertiary hospitals 
in Northern Vietnam (National Hospital of Tropical 
Diseases and 103 Military Hospital). Isolating from 
hospitalized BSIs patients in two hospitals 56 E. coli 
strains were inoculated in BHI Broth with 20% glycerol 
after being identified at the labs of these two hospitals. 
Antimicrobial susceptibility assessed through 
MIC test by VITEK
®
2 Compact (BioMérieux, France and 
provided by DEKA Limited Liability Company) 
standardized by CLSI [16]. Antibiotics which has been 
used are were (with number coding - abbreviation): 
amikacin (1-AK), ampicillin (2-AM), ceftazidime (3-
CAZ), ciprofloxacin (4-CIP), ceftriaxone (5-CRO), 
cefazolin (6-CZ), doripenem (7-DOR), ertapenem (8-
ETP), cefepime (9-FEP), gentamycin (10-GM), 
levofloxacin (11-LVX), ampicillin/sulbactam (12-SAM), 
trimethoprim/sulfamethoxazole (13-SXT), tobramycin 
(14-TM) , piperacillin/tazobactam (15-TZP). 
Using QIAamp DNA Mini Kit (USA) for DNA 
extraction (including isolation and quantification), we 
performed the experimental procedure according to 
manufacturer’s instruction. PCR amplification 
performed in PCR master mix (Invitrogen – USA) that 
consisted of 200 µM of each dNTPs (dATP, dCTP, 
dGTP, dTTP), 100 pM primers, 1 U Taq DNA 
polymerase, 10 mM Tris-HCl, 50 mM KCl, 1,5 mM 
MgCl2 and 10 µl DNA template. Specific primers for 
blaTEM, blaSHV, blaCTX-M, blaPER genes showed in Table 
1. The experiments were performed using the protocol 
with 30 cycles that each of them consisted of 3 steps 
including denaturing (95°C for 30 seconds), annealing 
(58, 57, 60, 54°C for 30 seconds), elongating (72°C 
for 1 minute). PCR products were performed 
electrophoresis, imaged routinely and sequenced. The 
sequence of PCR products was compared with the 
original gene’s sequence on GenBank to confirm 
blaTEM, blaSHV, blaCTX-M and blaPER gene. 
Table 1: Specific primers for blaTEM, blaSHV, blaCTX-M, 
blaPER genes 
Target 
gene 
Primer Nucleotide sequence (5’ – 3’) Size (bp) 
AT 
(°C) 
blaTEM 
TEM-F 
TEM-R 
5’ – TGC GGT ATT ATC CCG TGT TG – 3’ 
5’ – TCG TCG TTT GGT ATG GCT TC – 3’ 
300 52.2 
blaSHV 
SHV-F 
SHV-R 
5’ – TCT CCC TGT TAG CCA CCC TG – 3’ 
5’ – CCA CTG CAG CAG CTG C – 3’ 
600 51.2 
blaCTX-M 
CTX-M-F 
CTX-M-R 
5’ – CGA TGT GCA GTA CCA GTA A – 3’ 
5’ – TTA GTG ACC AGA ATC AGC GG – 3’ 
650 60 
blaPER 
PER-F 
PER-R 
5’ – ATG AAT GTC ATT ATA AAA GC – 3’ 
5’ – TTA ATT TGG GCT TAG GGC AGA A – 3’ 
933  
 
Statistical Analysis 
The statistical analysis was conducted using 
the R language [17]. Graphics also were performed by 
R language (version 3.5.2). The analysis of such 
enormous volumes of information in the acquisition of 
data from 56 strains, each strain companion with 
subtype genes (three blaTEM subtypes, four blaCTX-M 
subtypes, eight blaSHV subtypes) and 15 antibiotics 
with 3 level of resistance (susceptible, intermediate, 
resistance). For this reason, we used R language to 
analyze. 
 
 
Results 
 
Clinical characteristics of the patient in this 
study showed in Table 2. 
Table 2: Clinical characteristics of patients 
Age (subgroup) 
16-19 
20-29 
30-39 
40-49 
50-59 
≥ 60 
 
0 (0) 
8 (14.29) 
3 (5.36) 
9 (16.07) 
17 (30.35) 
19 (33.93) 
Gender 
Male 
Female 
 
37 (66.07) 
19 (33.93) 
History of medical condition 
Cirrhosis 
Self-report alcoholism 
Diabetes 
Hypertension 
Long-term corticosteroid use 
Renal failure 
Pregnancy 
Spinal cord injury 
Urinary tract stone 
Heart failure 
Cancer 
No 
 
13 (23.21) 
10 (17.86) 
8(14.29) 
6 (10.71) 
4 (7.14) 
2 (3.57) 
2 (3.57) 
1 (1.79) 
1 (1.79) 
1 (1.79) 
1 (1.79) 
7 (12.5) 
Time to hospitalization 
< 5 
5-14 
> 14 
 
40 (71.43) 
14 (25.00) 
2 (3.57) 
 
Among 56 E. coli strains isolated analyzed, 
39.3% strains were identified as producing ESBL. 
Detail information of sequencing results showed in 
Table 3 highlighting three blaTEM subtypes (blaTEM 1, 
blaTEM 79, blaTEM 82), four blaCTX-M subtypes (blaCTX-M-
15, blaCTX-M-73, blaCTX-M-98, blaCTX-M-161), and eight 
blaSHV subtypes (blaSHV-5, blaSHV-7, blaSHV-12, blaSHV-
15, blaSH -24, blaSHV-33, blaSHV-57, blaSHV-77). 
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Table 3: ESBL-producing E. coli strains and ESBL encoding 
genes 
Result Number of strains (n = 56) 
Percentage (%) 
 
ESBL-positive 22 (39.29 %) 
ESBL-negative 34 (60.71 %) 
blaTEM  
TEM-1 
TEM-79 
TEM-82 
 
56 
34 
19 
3 
blaCTX-M  
CTX-M-15 
CTX-M-73 
CTX-M-98 
CTX-M-161 
 
43 
12 
11 
17 
3 
 
blaPER 0 
blaSHV  
SHV-5 
SHV-7 
SHV-12 
SHV-15 
SHV-24 
SHV-33 
SHV-57 
SHV-77 
16 
3 
2 
6 
1 
1 
1 
1 
1 
blaTEM + blaCTX-M 32 (57.2 %) 
blaTEM + blaSHV 5 (8.9 %) 
blaTEM + blaSHV + blaCTX-M 11 (19.6 %) 
 
The results of gene analysis revealed that 
100% of isolates harbored blaTEM gene, but none of 
them had the blaPER gene (Table 4). The prevalence 
of blaCTX-M gene of overall strains, ESBL-producing, 
and non-ESBL-producing were 76.79%, 81.8%, and 
73.5%, respectively. The prevalence of blaSHV gene 
among ESBL-producing and non-ESBL-producing 
strains were 18.2% and 35.3%. More information 
showed in Table 4. 
Table 4: Encoding gene of ESBL subtypes 
 
Gene 
ESBL-positive 
(n = 22) 
ESBL-negative 
(n = 34) 
(+) (-) (+) (-) 
n (%) n (%) N (%) n (%) 
blaPER   22 100   34 100 
blaTEM  
 
22 100   34 100   
blaTEM + blaCTX-M 18 81.82 4 18.18 25 73.53 9 26.47 
blaTEM + blaSHV 4 18.18 18 81.82 12 35.29 22 64.71 
blaTEM + blaSHV + blaCTX-M 3 13.64 19 86.36 8 23.53 26 76.47 
 
Figure 1 showed a high prevalence of 
resistance to ampicillin (AM-85.7% of strains), 
trimethoprim/sulfamethoxazole (STX-64.3% of 
strains), cephazolin (CZ-50% of strains), ciprofloxacin 
(CP-35.7% of strains) and levofloxacin (LVX-35.7% of 
strains).  
 
Figure 1: Antibiotic resistance profile; Antibiotics are 1 to 15 
following 15 antibiotic have been coded Amikacin (1-AK); Ampicillin 
(2-AM); Ceftazidime (3-CAZ); Ciprofloxacin (4-CIP); Ceftriaxone (5-
CRO); Cefazolin (6-CZ); Doripenem (7-DOR); Ertapenem (8-ETP); 
Cefepime (9-FEP); Gentamycin (10-GM); Levofloxacin (11-LVX); 
Ampicillin/Sulbactam (12-SAM); Trimethoprim/sulfamethoxazole 
(13-SXT); Tobramycin (14-TM); Piperacillin/Tazobactam (15-TZP) 
 
Figure 2 showed highly active antibiotics such 
as doripenem (DOR-96.4% of strains), ertapenem 
(ETP-94.6% of strains), amikacin (AK-96.4% of 
strains), and cefepime (PEP-89.3% of strains). In 
each antibiotic, detail information of genes was 
shown. 
 
Figure 2: Antibiotic sensitivity profile; Antibiotics are 1 to 15 
following 15 antibiotic have been coded Amikacin (1-AK); Ampicillin 
(2-AM); Ceftazidime (3-CAZ); Ciprofloxacin (4-CIP); Ceftriaxone (5-
CRO); Cefazolin (6-CZ); Doripenem (7-DOR); Ertapenem (8-ETP); 
Cefepime (9-FEP); Gentamycin (10-GM); Levofloxacin (11-LVX); 
Ampicillin/Sulbactam (12-SAM); Trimethoprim/sulfamethoxazole 
(13-SXT); Tobramycin (14-TM); Piperacillin/Tazobactam (15-TZP) 
 
Figure 3 showed that in patients who carried 
gene had high rate of antibiotic resistance with the 
main antibiotics were ceftazidime (3-CAZ), cefazolin 
(6-CZ), doripenem (7-DOR), gentamycin (10-GM), 
levofloxacin (11-LVX), ampicillin/sulbactam (12-SAM), 
trimethoprim/sulfamethoxazole (13-SXT) in line with 
blaCTX-M gene with the same allocation. Tobramycin 
(14-TM) with intermediate response had blaSHV and 
blaTEM as main genes. Figure 3 supported Figures 1 
and 2 to visualize the association between gene and 
antibiotic resistance. 
 
Figure 3: The antibiotic resistance level with genes. Gen antibiotic is 
1 to 5 following CTX-M gene, ESBL gene, PER gene, SHV gene 
and TEM gene; Anti – biotic RSI is 1 to 3 following R (resistance), S 
(sensitive), I (intermediate); Antibiotics are 1 to 15 following 15 
antibiotic have been coded Amikacin (1-AK), Ampicillin (2-AM), 
Ceftazidime (3-CAZ), Ciprofloxacin (4-CIP), Ceftriaxone (5-CRO), 
Cefazolin (6-CZ), Doripenem (7-DOR), Ertapenem (8-ETP), 
Cefepime (9-FEP), Gentamycin (10-GM), Levofloxacin (11-LVX), 
Ampicillin/Sulbactam (12-SAM), Trimethoprim/sulfamethoxazole 
(13-SXT), Tobramycin (14-TM) , Piperacillin/Tazobactam (15-TZP) 
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Table 5 clarified the detail of antibiotic 
resistance with the ESBL gene. While ESBL-positive 
strains were highly resistant to ampicillin (AM), 
ceftriaxone (CRO), cephazolin (CZ), and 
trimethoprim/sulfamethoxazole (SXT) at the rate of 
100%, 100%, 100%, and 81.8%, respectively, ESBL-
negative strains had a lower prevalence of resistance 
to these agents at the rate of 76.5%, 11.8%, 17.7%, 
and 53%, respectively. Both groups were susceptible 
to doripenem (DOR), ertapenem (ETP), and amikacin 
(AK) at the rate of more than 90%. 
Table 5: The antibiotic resistance profile of ESBL subtype 
Antimicrobial Agents 
ESBL-positive 
(n = 22) 
ESBL-negative 
(n = 34) 
S 
(%) 
I 
(%) 
R 
(%) 
S 
(%) 
I 
(%) 
R 
(%) 
Ampicilin    22 (100) 7 (20.59) 
1 
(2.94) 
26 (76.47) 
Ceftriaxone    22 (100) 30 (84.24)  4 (11.76) 
Cephazolin    22 (100) 27 (79.41) 
1 
(2.94) 
6 (17.65) 
Trimethoprim/ 
sulfamethoxazole 
4 
(18.18) 
 18 (81.82) 16 (47.06)  18 (52.94) 
Ampicilin/sulbactam 10 (45.45)  12 (54.55) 13 (38.24) 
8 
(23.53) 
13 (38.24) 
Ciprofloxacin  
11 
(50) 
 
11 
(50) 
25 (73.53)  9 (26.47) 
Levofloxacin  
11 
(50) 
 
11 
(50) 
25 (73.53)  9 (26.47) 
Piperacilline/ 
Tazobactam 
11 (73.33) 
2 
(13.33) 
2 (13.33) 19 (82.61) 
1 
(4.35) 
3 (13.04) 
Ceftazidime  15 (68.18)  7 (31.82) 30 (88.24)  4 (11.76) 
Cefepime  18 (81.82) 
1 
(4.55) 
3 (13.64) 22 (94.12)  
2 
(5.88) 
Doripenem 
22 
(100) 
  32 (94.12)  
2 
(5.88) 
Ertapenem  21 (95.45) 
1 
(4.55) 
1 
(4.55) 
32 (94.12)  
2 
(5.88) 
Amikacin  
22 
(100) 
  32 (94.12)  
2 
(5.88) 
Gentamycin  15 (68.18)  7 (31.82) 25 (73.53) 
1 
(2.94) 
8 (23.53) 
Tobramycin  14 (63.64) 
5 
(22.73) 
3 (13.64) 25 (73.53) 
7 
(20.59) 
2 
(5.88) 
 
 
 
Discussion 
 
ESBL-producing E. coli is common genotypes 
and its incidence varies from region to region. ESBLs 
are typically inhibitor-susceptible B-lactamases that 
are encoded by mobile genes with the blaCTX-M, blaSHV, 
and blaTEM families were the most frequently. In our 
study, among 56 E. coli strains have been analyzed, 
39.3% strains were identified as ESBL-producing. Our 
finding is higher than that of study in Northern, 
Vietnam (25.1% of strains produced ESBL among 
Enterobacteriaceae) [15]. Comparing with other 
countries, it is higher than Singapore (33%) [18], Chile 
(23.8%) and Brazil (12.8%) but lower than that of India 
(60%), Hong Kong (48%) [18] Mexico (48.4%) [19]. All 
cases with ESBL-producing E. Coli had blaTEM gene 
and the 100% resistance to ampicillin was found that 
in line with the present study [20].  
Our results about blaCTX-M gene also 
corroborated another study that reported blaCTX-M bla 
(beta-lactamase) gene was common in all the ESBL 
isolates [21]. This result is also in agreement with 
study Gurntke et al., of that among 19% ESBL-
positive cases, blaCTX-M-15 was the most common 
genotypes (60%), followed by blaSHV-5 (27%) [22]. 
Other studies showed the same results with blaCTX-M-
14 (48% of the isolates) were the most frequent ESBL 
[11], [23]. It was observed that the predominant of 
subtypes blaCTX-M gene was diverse from study to 
study. Analyzing 552 isolates from BSIs that 
resistance to third-generation cephalosporin showed 
more detail with blaCTX-M-15 (50%), blaCTX-M-14 (14%), 
blaCTX-M-27 (11%) and blaCTX-M-101 (5%) [24]. 
ESBL-producing E. Coli in BSIs have been 
shown a substantial increase in the 21
st
 century [25]. 
Besides that, its burden was growing worldwide [26]. 
Finding the appropriate therapy became crucial and 
carbapenems emerged as 'best therapy' for ESBL-
producing bacteria [25]. But in the time of antibiotics 
and resistance becoming popular, E. Coli also starts 
resistance to carbapenem that leading a high financial 
burden and increased mortality [27].  
The knowledge of antibiotic resistance profile 
is key in clinical practice. The high rate of resistance 
to some routine antibiotic agents which were 
commonly used in most hospitals in our area was 
provided in this study. The results also showed that 
amikacin and carbapenems (doripenem and 
ertapenem) emerged as choices for empiric therapy 
instead. Sinha et al., showed similar findings with high 
prevalence of ESBL-positive, high rate of resistance to 
ampicillin (86%), ceftriaxone (80.6%), and 
fluoroquinolones (80%) and the clear choice for 
empirical treatment were carbapenems in these cases 
[21]. 
Knowing the risk factors of antibiotic 
resistance is crucial for management strategy. The 
time before hospitalization was an only independent 
risk factor among ESBL in BSIs [28] while previous 
use of oxyimino-beta-lactams was the only modifiable 
risk factor among nosocomial BSIs [11]. In our study, 
ESBL encoding genes showed high correlation with 
antibiotic resistance.  
While ESBL-positive strains were highly 
resistant to ampicillin, ceftriaxone, cephazolin, and 
trimethoprim/sulfamethoxazole at the rate of 100%, 
100%, 100%, and 81.8%, respectively, ESBL-negative 
strains showed a lower prevalence of resistance to 
these agents at the rate of 76.5%, 11.8%, 17.7%, and 
53%, respectively. Both groups were susceptible to 
doripenem, ertapenem, and amikacin at the rate of 
more than 90%. This finding was similar to the study 
in Finland from 1999 to 2013 that showed most (88%) 
of the isolates reported as non-susceptible to third-
generation cephalosporins had ESBL phenotype [29]. 
In conclusion, in Escherichia coli causing 
bloodstream infections, antibiotic resistance was 
higher in ampicillin, trimethoprim/sulfamethoxazole 
and cephazolin Antibiotics was highly susceptible 
including doripenem, ertapenem, amikacin, and 
cefepime. 
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Ethical approval 
 
This study is approved by the ethics 
committee of National Hospital of Tropical Diseases 
and Military Hospital 103. 
 
 
Ethical considerations 
 
The protocol was approved by the Ethics 
Committee of both National Hospital of Tropical 
Diseases and 103 Military Hospital. The study was in 
line with the Declaration of Helsinki. Written informed 
consent has been provided to all participants with full 
explanation. After that, the blood samples were 
collected.  
 
Informed consent 
 
The consent and commitment were signed by 
the patients in the study. 
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